Brian's Journal
To submit your own tribute about Brian here, please email us at ICANCancerPrograms@askican.org and we will post it within 24 hours. Please include your phone number.
The Brian Allman Diffuse Large B Cell Lymphoma (DLBCL) Novel Therapeutics Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.
Federal Tax I.D.: EIN 86-0818253